 |
| Dear StockNews Member, Monday morning we will release the next exciting stock from our potent Stocks Under $10 strategy, boasting +57.82% average annual returns! Here’s why our Chief Growth Strategist, Meredith Margrave, is so bullish on this low-priced stock poised to become your next BIG winner: “This clinical-stage biopharmaceutical company looks set to take off into the stratosphere thanks to surging demand for its effective treatments. We're talking potential upside of 200%... 300%... even more as this market grows. Between leading products already on the market and a strong pipeline of future candidates in clinical trials, it's just a matter of time before these $5 shares explode to $10 and beyond.” To get full details on this hot stock (including company name and ticker), you simply need to take a 30 day trial to our POWR Stocks Under $10 Newsletter. And then you will get the trade alert Monday morning, April 10th. And the cost? Just $1… Yes, for only $1 you can start a 30 day trial that kicks off with this explosive pick, plus full access to the entire POWR Stocks Under $10 portfolio—the same portfolio that produced a real life 400% winner for members this past year. PLUS every new trade over the next 30 days. Note there is zero obligation beyond the $1 trial. However, I’m confident that once you experience this outperforming service harnessing our most potent trading strategy that you will want to remain a member for a long, long time. And if I am wrong and you don’t like what you see… then simply cancel and pay nothing more. So get started today and experience the market-shattering returns of POWR Stocks Under $10 for yourself. And be lined up for that key trade on Monday morning! Start 30 Day Trial for Just $1 >> Wishing you a world of investment success!
|
| This email was sent to edwardlorilla1986.paxforex@blogger.com You are receiving this email because you opted in at our website at StockNews.com. StockNews.com 1 Penn Plaza, 39th Floor New York, NY 10119 Unsubscribe from this list |
| StockNews.com | Terms of Use | Performance | Privacy Policy |
No comments:
Post a Comment